Posted by Michael Wonder on 06 Aug 2021
Formycon and Bioeq announce submission of the biologics license application for FYB201, a biosimilar candidate to Lucentis (ranibizumab) to the U.S. FDA
5 August 2021 - Formycon and its license partner Bioeq announce that the biologics license application for FYB201, Formycon’s biosimilar candidate to Lucentis, has been recently submitted to the U.S. FDA.
If approved, Coherus BioSciences will commercialise FYB201 (also known as CHS-201) in the United States of America per the terms of the November 2019 license and development agreement between Bioeq and Coherus.
